Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 and dose expansion study of APR-246 in combination with ibrutinib or venetoclax-based therapy in subjects with TP53-mutant relapsed and/or refractory non-hodgkin lymphomas (NHL) including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
    Meeting Abstract

    Thompson, M. C.; Davids, M. S.; Jain, N.; Soumerai, J. D.; Geethakumari, P. R.; Gubits, A.; Hickman, D.; Wennborg, A.; Attar, E. C.; Abdel-Wahab, O.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen
    Meeting Abstract

    Thompson, M. C.; Allan, J. N.; Sail, K.; Manzoor, B. S.; Pu, J. J.; Barr, P. M.; Coombs, C. C.; Schuster, S. J.; Skarbnik, A.; Rhodes, J. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Male-biased spliceosome mutations in blastic plasmacytoid dendritic cell neoplasm (BPDCN) impair pDC activation and apoptosis
    Meeting Abstract

    Togami, K.; Chung, S. S.; Madan, V.; Kenyon, C. M.; Cabal-Hierro, L.; Taylor, J.; Kim, S.; Griffin, G. K.; Ghandi, M.; Li, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A phase 1 study of LY3410738, a first-in-class covalent inhibitor of mutant IDH in advanced myeloid malignancies (trial in progress)
    Meeting Abstract

    Stein, E. M.; Konopleva, M.; Gilmour, R.; Szpurka, A. M.; Hill, E.; Ward, R.; Kantarjian, H. M.; Dinardo, C. D.
    Blood (2020)

    Fulltext@MSK | Save
  • The tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma
    Meeting Abstract

    Takata, K.; Chong, L. C.; Ennishi, D.; Thakur, A.; Healy, S.; Viganò€, E.; Dao, T.; Nielsen, J. S.; Ben-Neriah, S.; Aoki, T.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial results from a biomarker-directed phase 2 trial of SY-1425, a potent and selective RAR alpha agonist, in combination with azacitidine in relapsed/refractory acute myeloid leukemia
    Meeting Abstract

    Stein, E. M.; De Botton, S.; Cluzeau, T.; Pigneux, A.; Liesveld, J. L.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Braun, T.; Bixby, D. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial
    Meeting Abstract

    Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save